Your browser doesn't support javascript.
loading
Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients.
Polanski, Jose F; Tanaka, Eloise A; Barros, Harymy; Chuchene, Adriana G; Miguel, Patricia T G; Skare, Thelma L.
Afiliación
  • Polanski JF; Department of Otorhinolaryngology-Head and Neck Surgery, Federal University of Parana, and Mackenzie Evangelical School of Medicine-Parana, Curitiba, Brazil.
  • Tanaka EA; Rheumatology Clinic, Mackenzie Evangelical University Hospital, Mackenzie Evangelical School of Medicine -Parana, Curitiba, Brazil.
  • Barros H; Rheumatology Clinic, Mackenzie Evangelical University Hospital, Mackenzie Evangelical School of Medicine -Parana, Curitiba, Brazil.
  • Chuchene AG; Audiology Clinic, Mackenzie Evangelical University Hospital, Mackenzie Evangelical School of Medicine-Parana, Curitiba, Brazil.
  • Miguel PTG; Audiology Clinic, Mackenzie Evangelical University Hospital, Mackenzie Evangelical School of Medicine-Parana, Curitiba, Brazil.
  • Skare TL; Rheumatology Clinic, Mackenzie Evangelical University Hospital, Mackenzie Evangelical School of Medicine -Parana, Curitiba, Brazil.
Laryngoscope ; 131(3): E957-E960, 2021 03.
Article en En | MEDLINE | ID: mdl-32603516
OBJECTIVES/HYPOTHESIS: Antimalarial drugs (chloroquine and hydroxychloroquine) are widely used for the treatment of systemic lupus erythematosus (SLE). However, these drugs may have side effects such as hearing loss. This study aimed to describe the hearing function in SLE patients using antimalarials. Secondarily, this study aimed to investigate whether SLE causes hearing loss and if there are any serological or clinical aspects of this diseases associated with inner ear damage. STUDY DESIGN: Cross-sectional study. METHODS: This study included 84 individuals (43 SLE patients and 41 controls) with audiometry and tympanometry tests. Epidemiological, clinical, serological, and treatment profiles of SLE patients were extracted from the charts. RESULTS: SLE patients had more sensorineural hearing loss than controls (23.2% vs. 0; P = .001). Pure-tone averages in SLE patients using antimalarials and not using antimalarials were similar (8.75 vs. 8.75; P = .63). At 8,000 Hz, antimalarial dug nonusers performed worse than users (10.00 vs. 22.50; P = .03). Tympanometry was normal in all participants. SLE serological and clinical profiles in patients with and without hearing loss were the same (all P = nonsignificant). CONCLUSIONS: There is a high prevalence of hearing loss in SLE that is not affected by antimalarial drug use. LEVEL OF EVIDENCE: 3b Laryngoscope, 131:E957-E960, 2021.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cloroquina / Pérdida Auditiva Sensorineural / Hidroxicloroquina / Lupus Eritematoso Sistémico / Antimaláricos Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Laryngoscope Asunto de la revista: OTORRINOLARINGOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cloroquina / Pérdida Auditiva Sensorineural / Hidroxicloroquina / Lupus Eritematoso Sistémico / Antimaláricos Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Laryngoscope Asunto de la revista: OTORRINOLARINGOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Estados Unidos